Compared with patients with blood group O or B, a higher proportion of COVID-19 patients with blood group A or AB required mechanical ventilation and continuous renal replacement therapy.
Researchers conducted a study to examine whether plasma biomarkers can differentiate collegiate athletes who return to sports participation in less than 14 days or 14 days or more following a sports-related concussion.
Investigators assess underlying mechanisms and relevant biomarkers of morbidity and mortality due to coagulopathy in patients with severe COVID-19 infection.
Among patients with cancer, tumor subtypes may influence varying susceptibility to SARS-CoV-2 and COVID-19 disease phenotypes.
Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.
In expanded research, investigators studied the effects of therapeutic and prophylactic anticoagulation treatment in hospitalized patients with COVID-19.
A team of investigators sought to determine whether endotheliopathy is involved in COVID-19–associated coagulopathy pathogenesis.
Researchers from the Houston Methodist Hospital examined the efficacy of COVID-19 convalescent plasma transfusion vs standard of care.
Several questions remain regarding the effect of COVID-19 infection and hypercoagulation in the management of patients taking oral contraceptives, estrogen therapy, and patients who are pregnant.
Due to the COVID-19 pandemic, patterns of blood transfusion demands are not certain; therefore, institutions should plan for a reduction in donations.
Distinct RNA signatures are evident in peripheral blood of rheumatoid arthritis patients before a disease flare.
Although the association between thrombocytosis in iron deficiency anemia is understood, researchers studied the risk for thrombotic complications.
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
Readmissions for CRS, neurotoxicity, infection, and other adverse events are common after immunotherapy with axicabtagene ciloleucel.
Hypercoagulable thromboelastography can predict thrombotic events in patients with COVID-19 in the intensive care unit.
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
Researchers compared 4 phototherapy methods and evaluated phototherapy duration and decline to reduce total serum bilirubin levels in infants.
Six months after hematopoietic stem cell transplantation, nearly 20% of enrolled patients had experienced clinically significant PTSD symptoms.
The FDA has approved Artesunate for Injection (Amivas) for the initial treatment of severe malaria in adult and pediatric patients.
Survivors of childhood hematologic malignancies with poorly reported patient outcomes may have more chronic health conditions, regardless of treatment method.